Drug

C-Met Inhibitor HS-10241 clinical trials

Also written HS-10241.

studies test it: 7
open now: 2
in phase 3: 1
first study started: 2016

Keep track of what changes. Save the c-Met Inhibitor HS-10241 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Development codes

HS-10241: 6

Combined with it in one product

HS-10241+ Almonertinib: 1

Studies by the year they started

7 studies that test it; most in 2016 (2)

Studies that test c-Met Inhibitor HS-10241, by start year
Year	Studies
2016	2
2017	1
2019	1
2022	1
2023	1
2025	1

By phase

A phase 1/2 study counts in both.

Phase 1: 6
Phase 3: 1

What it is tested for

Each study’s main condition, where its own words name it.

Neoplasms: 3
Carcinoma, Non-Small-Cell Lung: 3

Who runs them

Industry 7 · Other 0

Jiangsu Hansoh Pharmaceutical Co., Ltd. (6) · Atridia Pty Ltd. (1)

Often tested with

Tested in the same studies.

Aumolertinib (1) · Apatinib (1)

Studies

Open first, then newest update. How each study uses c-Met Inhibitor HS-10241 is read from its arms, and is right about nine times in ten.